CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $916.08M, above the global median of $520.53M
- PositionCurrent ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.64×)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
790.24BKRW559.52M · vs all stocks (USD)
Revenue (TTM)
1.29TKRW916.08M · vs all stocks (USD)
Profit Margin
-5.68%vs Biotechnology peers
Beta
0.5910xvs all stocks
52-Week Change
-21.59%vs all stocks
Market Capitalization
790.24BKRW559.52M · vs all stocks (USD)
Enterprise Value
1.87TKRW1.32B · vs all stocks (USD)
Price to Sales (TTM)
0.6532xvs Biotechnology peers
Price to Book (MRQ)
0.7429xvs Biotechnology peers
Enterprise to Revenue
1.44xvs Biotechnology peers
Enterprise to EBITDA
-103.80xvs Biotechnology peers
Gross Margin
27.06%vs Biotechnology peers
Profit Margin
-5.68%vs Biotechnology peers
Operating Margin
-9.26%vs Biotechnology peers
Return on Assets (TTM)
-1.88%vs Biotechnology peers
Return on Equity (TTM)
-14.09%vs Biotechnology peers
Revenue (TTM)
1.29TKRW916.08M · vs all stocks (USD)
Revenue per Share (TTM)
17.17KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
8.40%vs Biotechnology peers
Gross Profit (TTM)
357.54BKRW253.15M · vs all stocks (USD)
EBITDA (TTM)
4.93BKRW3.49M · vs all stocks (USD)
Net Income (TTM)
-73.45BKRW-52.01M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
8.41%vs Biotechnology peers
Operating Cash Flow (TTM)
-102.92BKRW-72.87M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-261.07BKRW-184.85M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
504.64BKRWFY2025 · Dec 31, 2025Revenue
1.27TKRWFY2025 · Dec 31, 2025Cost of Goods Sold
904.50BKRWFY2025 · Dec 31, 2025Gross Profit
363.75BKRWFY2025 · Dec 31, 2025Operating Income
-48.44BKRW-34.30M · vs all stocks (USD)
Pre-tax Income
-143.26BKRWFY2025 · Dec 31, 2025Income Tax Expense
3.45BKRWFY2025 · Dec 31, 2025Net Income
-146.71BKRWFY2025 · Dec 31, 2025EBIT
-88.42BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
4.93BKRWFY2025 · Dec 31, 2025Research & Development
24.59BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
184.46BKRWFY2025 · Dec 31, 2025Other Operating Expenses
26.63BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
11.46BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
54.85BKRWFY2025 · Dec 31, 2025EPS (Basic)
-1.64KKRWFY2025 · Dec 31, 2025EPS (Diluted)
-1.65KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
67.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
67.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-146.71BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
36.83BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-142.06BKRWFY2025 · Dec 31, 2025Free Cash Flow
-242.59BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
237.56BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-146.71BKRWFY2025 · Dec 31, 2025Stock-based Compensation
201.48MKRWFY2025 · Dec 31, 2025Other Non-cash Items
52.16BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.29BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-37.42BKRWFY2025 · Dec 31, 2025Capital Expenditures
-100.53BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-4.71BKRWFY2025 · Dec 31, 2025Net Acquisitions
-75.79BKRWFY2025 · Dec 31, 2025Purchase of Investments
-162.74BKRWFY2025 · Dec 31, 2025Sale of Investments
229.64BKRWFY2025 · Dec 31, 2025Other Investing Activity
-26.27BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-135.69BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
104.70BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-84.56BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-10.39BKRWFY2025 · Dec 31, 2025Other Financing Charges
-1.72BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
189.75BKRWFY2025 · Dec 31, 2025Shares Outstanding
92.97MSharesUpdated Aug 19, 2026Float Shares
70.05MSharesUpdated Aug 19, 2026% Held by Insiders
24.64%vs all stocks
% Held by Institutions
8.88%vs all stocks
Total Cash (MRQ)
435.81BKRW308.57M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.90KKRWUpdated Aug 19, 2026Total Debt (MRQ)
952.32BKRW674.28M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9352xvs Biotechnology peers
Current Ratio (MRQ)
0.8810xvs Biotechnology peers
Book Value per Share (MRQ)
11.44KKRWUpdated Aug 19, 2026Total Assets
2.55TKRW1.80B · vs all stocks (USD)
Total Current Assets
888.14BKRWFY2025 · Dec 31, 2025Total Liabilities
1.74TKRWFY2025 · Dec 31, 2025Total Non-current Assets
1.66TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
415.14BKRWFY2025 · Dec 31, 2025Total Current Liabilities
1.32TKRWFY2025 · Dec 31, 2025Cash Equivalents
237.56BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
237.56BKRWFY2025 · Dec 31, 2025Other Short-term Investments
101.67BKRWFY2025 · Dec 31, 2025Accounts Receivable
134.96BKRWFY2025 · Dec 31, 2025Inventory
59.60BKRWFY2025 · Dec 31, 2025Accounts Payable
57.59BKRWFY2025 · Dec 31, 2025Short-term Debt
680.91BKRWFY2025 · Dec 31, 2025Other Current Liabilities
19.97BKRWFY2025 · Dec 31, 2025Long-term Debt
224.52BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
9.66BKRWFY2025 · Dec 31, 2025Common Stock (Book)
39.65BKRWFY2025 · Dec 31, 2025Retained Earnings
164.80BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
809.25BKRW572.98M · vs all stocks (USD)
Treasury Stock
3.58BKRWFY2025 · Dec 31, 202552-Week Low
7.60KKRWUpdated Aug 19, 202652-Week High
23.95KKRWUpdated Aug 19, 202652-Week Change
-21.59%vs all stocks
Beta
0.5910xvs all stocks
50-Day MA
10.20KKRWUpdated Aug 19, 2026200-Day MA
14.93KKRWUpdated Aug 19, 2026Avg 10-Day Volume
269.45KSharesUpdated Aug 19, 2026Avg 30-Day Volume
290.95KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-1.65KKRWUpdated Aug 19, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Working Capital Pattern
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.88Industry median: 5.64Industry P5: 1.06Peers compared: 261
Debt-to-equity is 0.94×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 0.94Industry median: 0.09Industry P95: 0.88Peers compared: 261
Price-to-book is 0.74×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.74Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Altman Z-Score 0.54: distress zoneCritical
Altman Z-Score: 0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $916.08M, above the global median of $520.53MNotable
Revenue (USD): 916,075,827.209Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Shaanxi Kanghui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Sinobioway Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Careray Digital Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Boryung Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
HD Korea Shipbuilding & Offshore Engineering Co., Ltd.
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedWorking Capital PatternRevenue Growing With Receivables Growing
Nusantara Sejahtera Raya Tbk
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedWorking Capital PatternPartial Recovery After Sharp Decline
Installed Building Products Inc.
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedWorking Capital PatternRevenue Growing With Receivables Growing